Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $143.68 USD
Change Today +1.78 / 1.25%
Volume 731.2K
EW On Other Exchanges
Symbol
Exchange
New York
As of 4:15 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Key Developments

Edwards Lifesciences Corp. - Shareholder/Analyst Call

Edwards Lifesciences Corp. - Shareholder/Analyst Call

Edwards Lifesciences Corp. Announces Board Changes

Edwards Lifesciences Corporation announced two changes to the company's board of directors. Kieran T. Gallahue, chairman and chief executive officer of CareFusion Corporation, has been appointed to Edwards' board, effective immediately. Current director Mike R. Bowlin has expressed his desire to retire from the board and will not seek re-election at the annual stockholder meeting in May. Gallahue is currently on the executive committee of the board of the Advanced Medical Technology Association (AdvaMed).

Edwards Lifesciences Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter of 2015 and Revises Earnings Guidance for the Full Year 2015

Edwards Lifesciences Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net income of $109.2 million, or $1.00 per diluted share compared to $75.1 million, or $0.68 per diluted share a year ago. Income before provision for income taxes was $132.9 million compared to $100.3 million a year ago. Net sales were $680 million compared to $536 million a year ago. Non-GAAP net income of $116.5 million, or $1.06 per diluted share compared to $105.0 million, or $0.95 per diluted share a year ago. Net cash provided by operating activities was $93.2 million compared to $111.3 million a year ago. Non-GAAP free cash flow was $107.5 million compared to $91.2 million a year ago. Capital expenditures were $34.5 million compared to $20.1 million a year ago. This increase was driven primarily by a more profitable product mix and a positive impact from foreign exchange For the full year, the company reported net income of $811.1 million, or $7.48 per diluted share compared to $389.1 million, or $3.42 per diluted share a year ago. Income before provision for income taxes was $1,144.0 million compared to $511.2 million a year ago. Net sales were $2,322.9 million compared to $2,045.5 million a year ago. Non-GAAP net income of $379.6 million, or $3.50 per diluted share compared to $367.9 million, or $3.23 per diluted share a year ago. Net cash provided by operating activities was $1,022.3 million compared to $472.7 million a year ago. Non-GAAP free cash flow was $444.5 million compared to $306.4 million a year ago. Capital expenditures were $82.9 million compared to $109 million a year ago. The company provided earnings guidance for the first quarter of 2015 and revised earnings guidance for the full year 2015. Based on current foreign exchange rates, the company expects an approximate $160 million negative impact to full year 2015 reported sales compared to the prior year. The corresponding profit impact is mitigated by the company's foreign exchange hedging program. As a result, the company expects full year reported sales to be at the lower end of its previously provided $2.3 to $2.5 billion range. Given the momentum in transcatheter heart valve sales, the company is raising its full year 2015 diluted EPS guidance to $4.00 to $4.30, excluding special items. The company expects its gross profit margin for the full year 2015, excluding special items, to bump up to the range of 76% to 77%. This includes an estimated mix improvement of approximately 100 basis points over last year's adjusted gross profit margin of approximately 74% and currency impact of 100 to 200 basis points. The company continues to expect 15% to 25% underlying sales growth in 2015. For the full year 2015, the company continues to expect net interest expense to be approximately $10 million. Assuming a renewal again in 2015, the company continues to expect its full year tax rate to be between 21% and 23%. For the full year 2015, the company continues to expect free cash flow excluding special items to be between $375 million and $425 million. For the first quarter of 2015, at current foreign exchange rates the company projects total sales to be between $570 million and $610 million, and diluted earnings per share, excluding special items, to be between $1.02 and $1.10.

Edwards Lifesciences Corp. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 02:15 PM

Edwards Lifesciences Corp. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 02:15 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Scott B. Ullem, Chief Financial Officer and Corporate Vice President.

Edwards Lifesciences Corp. to Report Q4, 2014 Results on Feb 03, 2015

Edwards Lifesciences Corp. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Feb 03, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $143.68 USD +1.78

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $167.71 USD +1.05
Endo International PLC $90.04 USD +2.23
Hologic Inc $32.49 USD +0.55
Intuitive Surgical Inc $497.25 USD -1.74
Mettler-Toledo International Inc $323.29 USD +4.41
View Industry Companies
 

Industry Analysis

EW

Industry Average

Valuation EW Industry Range
Price/Earnings 19.0x
Price/Sales 6.6x
Price/Book 7.0x
Price/Cash Flow 18.9x
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.